5-amino-1MQ blocks the enzyme that throws away vitamin B3, and three currencies move at once

What NNMT actually does, and why blocking it does several things at once

The enzyme is nicotinamide N-methyltransferase, NNMT. Its job is simple to state: it takes nicotinamide — a form of vitamin B3 — and attaches a methyl group to it. A methyl group is a single carbon with three hydrogens, the smallest chemical tag cells use to mark things. The result is 1-methylnicotinamide, which the cell then excretes.

So NNMT is a disposal enzyme. It takes vitamin B3 and throws it away in a form that cannot be recycled.

Now look at what it consumes doing that, because this is where the compound gets interesting. The Nature paper that identified the target explains it precisely: "NNMT methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. Nicotinamide is a precursor of NAD(+), an important cofactor linking cellular redox states with energy metabolism. SAM provides propylamine for polyamine biosynthesis and donates a methyl group for histone methylation."

Unpack that and you get three separate consequences of one enzyme running.

It destroys NAD⁺ precursor. Nicotinamide is the raw material your cell uses to make NAD⁺, the molecule that carries electrons in every energy-producing reaction you run. Methylating nicotinamide takes it permanently out of that supply chain. Every NAD⁺ booster sold — nicotinamide riboside, NMN, plain niacinamide — is an attempt to push more material into the front of that chain. Inhibiting NNMT is an attempt to stop material leaking out of the back of it.

It burns through SAM. S-adenosylmethionine is the cell's universal methyl donor. It is what marks DNA and histones — the proteins your DNA is wound around — and those marks determine which genes are switched on. Every methylation reaction in your cell competes for the same SAM pool. An enzyme consuming SAM at high rates to dispose of vitamin B3 is spending a budget that gene regulation also draws on.

It competes with polyamine synthesis. SAM also supplies propylamine for making polyamines — spermidine and spermine — which the paper notes have "a major role in energy metabolism."

So one enzyme, three currencies. Inhibit it and all three should move at once. That is unusual, and it is why NNMT attracted interest as a target rather than as a curiosity.

The finding that started it

The 2014 Nature paper did not set out to study NNMT. It was looking at Glut4, the glucose transporter that fat cells lose in obesity and diabetes. Using gene arrays across mice engineered to lack or overexpress Glut4 in fat, the authors found "that nicotinamide N-methyltransferase (Nnmt) is the most strongly reciprocally regulated gene."

Most strongly, out of the whole array. That is the kind of result that redirects a laboratory. Then: "We report that NNMT expression is increased in WAT and liver of obese and diabetic mice."

And the experiment that made it a drug target: "Nnmt knockdown in WAT and liver protects against diet-induced obesity by augmenting cellular energy expenditure."

Note the mechanism named in that sentence. Not reduced appetite — increased energy expenditure. The mice were not eating less; their cells were spending more.

The paper then traced the pathway all the way through, and this is why it is a genuinely strong piece of work rather than an association. "NNMT inhibition increases adipose SAM and NAD(+) levels and upregulates ODC and SSAT activity as well as expression, owing to the effects of NNMT on histone H3 lysine 4 methylation in adipose tissue." So the SAM that was being spent on disposal became available, showed up as changed histone marks, and those marks turned up the enzymes that control polyamine flux.

Then they confirmed it in urine: "Direct evidence for increased polyamine flux resulting from NNMT inhibition includes elevated urinary excretion and adipocyte secretion of diacetylspermine, a product of polyamine metabolism."

That last step is what separates a mechanism from a story. They predicted a specific waste product should appear if their model was right, and it appeared.

Finally, oxygen consumption — the direct measure of a cell burning fuel — rose, "in an ODC-, SSAT- and PAO-dependent manner." Knock out the polyamine enzymes and the effect disappears, which demonstrates the pathway is the cause rather than a bystander.

The paper's own summary of what NNMT is: "a novel regulator of histone methylation, polyamine flux and NAD(+)-dependent SIRT1 signalling, and is a unique and attractive target for treating obesity and type 2 diabetes."

Where 5-amino-1MQ comes in

The 2014 work used genetic knockdown, which is not a drug. Turning it into one required a molecule that could get inside a cell, hit NNMT and not hit everything adjacent to it. That is the 2018 paper in Biochemical Pharmacology, and its title is the finding: "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice."

Three words in that title carry the work. Membrane-permeable: NNMT is inside the cell, so an inhibitor that cannot cross the membrane is useless regardless of how well it binds. Selective: the compound has to leave alone the structurally similar methyltransferases and the NAD⁺ salvage enzymes, or the effect is not attributable to NNMT. Reverse: the mice were already obese when treatment began.

The authors describe testing exactly those properties: "we investigated the permeability, selectivity, mechanistic, and physiological properties of a series of small molecule NNMT inhibitors. Membrane permeability of NNMT inhibitors was characterized using parallel artificial membrane permeability and Caco-2 cell assays. Selectivity was tested against structurally-related methyltransferases and nicotinamide adenine dinucleotide (NAD+) salvage pathway enzymes."

That is a careful drug-discovery paper rather than an enthusiastic one. Permeability measured two independent ways, selectivity measured against the enzymes most likely to confound the result.

The doses in that work were given by injection, several times daily, over days. That is the only dosing evidence that exists for this compound, and it is in mice.

Why the three currencies matter more than the fat loss

It is worth staying with the mechanism, because it is the reason this compound is discussed at all and it is almost always skipped in favour of the weight number.

NAD⁺. Every reaction that extracts energy from food hands electrons to NAD⁺. It also feeds the sirtuins, a family of enzymes that strip acetyl marks off proteins and cannot work without it, and PARP enzymes that repair damaged DNA and consume it heavily. NAD⁺ falls with age, and the entire supplement industry built on nicotinamide riboside and NMN exists to push more precursor into the front of that pathway. NNMT sits at the other end, quietly disposing of the same precursor. Blocking a leak and opening a tap are different interventions with the same intended effect, and nobody has compared them in a person.

SAM. Every methylation reaction in the cell — on DNA, on histones, on neurotransmitters, on phospholipids — draws from one shared pool of S-adenosylmethionine. That means these reactions compete. An enzyme spending SAM at high rates to throw away vitamin B3 is a competitor for the budget gene regulation uses, and the 2014 paper measured exactly that consequence: inhibiting NNMT changed histone H3 lysine 4 methylation in fat tissue. Gene expression shifted because a methyl budget was freed.

That is the part to sit with. This is not a drug that changes one number. It changes which genes are marked, in a tissue, by changing how a shared resource is spent. That is a powerful mechanism and it is precisely why the unstudied long-term consequences are not a formality.

Polyamines. Spermidine and spermine are involved in cell growth, autophagy and energy metabolism, and their flux is controlled by the rate-limiting enzymes the paper names — ODC, SSAT and polyamine oxidase. The oxygen-consumption increase in treated adipocytes disappeared when those enzymes were blocked, which is the strongest single piece of evidence in the whole literature that the polyamine arm is doing the work rather than accompanying it.

What the mouse numbers are and are not

The figures that circulate for this compound — body weight down, white fat mass down, adipocytes smaller, cholesterol lower, food intake unchanged — come from the 2018 small-molecule work in diet-induced obese mice, given by injection several times daily over days.

Two things about them. The unchanged food intake is the load-bearing detail, because it means the effect was on expenditure rather than on appetite, which is what the mechanism predicts and what makes the result internally consistent. And the species gap for metabolic endpoints is the widest in pharmacology: a mouse runs its metabolism several times faster per unit of mass than you do, carries proportionally far more brown fat, and is mildly cold-stressed at ordinary laboratory temperature, all of which flatter interventions that raise energy expenditure. That is the specific reason a long list of compounds that transformed mice did nothing in people.

So the numbers are real measurements of a real effect in an animal whose energy metabolism does not work like yours. Enough to justify pursuing the target. Not enough to predict a person.

What a page selling this will not tell you

There are no human trials. Not one. Not a phase I, not a safety study, not a pharmacokinetic run. Every number attached to 5-amino-1MQ came out of a mouse or a dish.

The core evidence is a knockdown, not the drug. The Nature paper's mechanistic depth — the histone marks, the polyamine flux, the diacetylspermine in urine, the enzyme-dependency controls — is all from genetic knockdown of NNMT. The small-molecule paper shows a molecule can reproduce the physiological outcome. It does not re-establish the whole mechanism.

NNMT is not only in fat. The 2014 paper reports NNMT elevated in white adipose tissue and liver. The enzyme is also expressed in other tissues and is studied heavily in cancer biology, where its role is not a simple one. Inhibiting a methyltransferase that influences histone methylation is not a local intervention, and the long-term consequences of shifting the SAM budget across tissues have not been studied in any species.

It is not a NAD⁺ booster, and it is not a peptide. It is a small molecule that stops NAD⁺ precursor being thrown away. That is a different mechanism from supplying more precursor, and the two have never been compared head to head in a person. It is also constantly sold as a peptide. It is not one — no amino acid chain, no injection requirement from its chemistry.

The regulation runs on glucose. A 2020 study found NNMT expression in adipocytes responds to glucose availability, with glucose deprivation increasing it. So the enzyme this compound blocks is itself under nutritional control, which means baseline diet is a variable in any effect and nobody has measured how large a one.

The interactions worth reasoning about, and why they cannot be listed

No drug-interaction work has been published for this compound. The enzymes that metabolise it, its half-life, its plasma protein binding — none of that exists in the literature, so anyone giving you a specific interaction list has written it rather than read it. What can be reasoned about is the mechanism, and three things follow from it.

Anything else acting on the NAD⁺ pool. Nicotinamide riboside, NMN, plain nicotinamide and niacin all push precursor into the pathway NNMT drains. Combining them is not obviously harmful and it is entirely unstudied, and there is a specific reason to be curious rather than confident: plain nicotinamide at high doses is itself a substrate for NNMT, so the interaction is not simply additive. Nobody has measured which way it goes.

Anything competing for the SAM pool. SAM-e as a supplement, methylfolate, methylcobalamin, betaine and choline all sit in the methylation economy, and so do the drugs that draw on it heavily — levodopa consumes SAM through COMT-mediated methylation, and so do several others. The whole premise of inhibiting NNMT is to change how a shared methyl budget is spent, which makes anything else spending from that budget a genuine unknown rather than a theoretical one.

Anything acting on polyamines or autophagy. Spermidine supplementation is sold on the same shelf and acts on the arm of this mechanism the 2014 paper showed to be load-bearing. Pushing the same pathway from two directions with no human data on either is compounding an unknown.

The honest summary of the interaction section is that there is nothing to report and specific reasons to expect the interactions are not trivial. That is more useful than a confident list somebody invented.

What it is genuinely useful for thinking about

The reason to know about NNMT is not that 5-amino-1MQ works. It is that the enzyme is the clearest published example of a single node where energy metabolism, gene regulation and polyamine flux intersect — and the 2014 paper walked the whole chain, from gene array to histone mark to urinary metabolite to oxygen consumption, with the controls to show the pathway was load-bearing.

What is unresolved is everything about the drug. Whether a person tolerates NNMT inhibition, at what dose, with what effect on the tissues where the enzyme does something other than dispose of vitamin B3, and whether the fat-loss effect survives translation out of an animal whose metabolic rate is several times yours. Those are not gaps in the reading. They are experiments that have not been run.

The name, and one thing it tells you

The name is a chemical description, and reading it is worth thirty seconds because it explains what the molecule is doing.

1MQ is 1-methylquinolinium — a quinoline ring carrying a methyl group on its nitrogen, which gives the nitrogen a permanent positive charge. The "5-amino" is an amine group added at the fifth position on that ring.

Now compare that to the enzyme's actual product. NNMT takes nicotinamide and methylates its ring nitrogen, producing 1-methylnicotinamide — a ring with a methylated, positively charged nitrogen. 5-amino-1MQ is a close structural imitation of that product, which is why it binds where it does. It is a product-mimicking inhibitor: the enzyme's own output, rebuilt in a form it cannot let go of.

Two practical things follow. It is a small aromatic molecule, not a peptide, whatever the shelf it is sold on says. And its permanent positive charge is precisely why the 2018 paper had to measure membrane permeability two separate ways — permanently charged molecules cross membranes poorly as a rule, and NNMT is inside the cell, so permeability was the real obstacle rather than binding. That the compound crosses at all is the actual achievement of that paper.

Everything above is what the published record supports. None of it is medical advice, and 5-amino-1MQ is sold for research use only, not for human consumption.